Frederic Gerges, MD
Interventional Pain Medicine · Boston, MANPI 1235310111
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Hydrocision, Inc. at 36.3% of the total. Reporting peaked in 2019 at $6,000 and has fallen 72.0% since, to $1,682 in 2025. Among interventional pain medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $75.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hydrocision, Inc.$8K
- Medtronic$7K
- Boston Scientific$1K
- AbbVie$1K
- Abbott$1K
- Lundbeck LLC$511
- plus $2K from 26 others
Across 1 payment — averaging $2804.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$3K
Across 7 payments — averaging $1164.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Hydrocision, Inc.$8K
What the payments were for
- Consulting fees$7,50036%
- Speaking & faculty fees$3,11215%
- Travel & lodging$3482%
- Food & beverage$9,63846%
- Entertainment$1671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hydrocision, Inc. | 9 | $7,544 |
| Medtronic(2 entities) | 65 | $6,515 |
| Boston Scientific | 27 | $1,351 |
| AbbVie(2 entities) | 62 | $1,256 |
| Abbott | 18 | $1,253 |
| Lundbeck LLC | 22 | $511 |
| Painteq LLC | 4 | $278 |
| Pfizer | 12 | $224 |
| Pacira Pharmaceuticals Incorporated | 1 | $221 |
| Relievant Medsystems, Inc. | 3 | $198 |
| Nevro Corp. | 4 | $181 |
| Bioness Inc | 1 | $167 |
| Si-bone, Inc. | 6 | $128 |
| Tersera Therapeutics LLC | 5 | $125 |
| Stimwave Technologies Incorporated | 4 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| Collegium Pharmaceutical, Inc. | 3 | $71 |
| Stryker | 2 | $68 |
| Vertos Medical, Inc. | 2 | $60 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Flowonix Medical Incorporated | 1 | $41 |
| Novartis | 2 | $39 |
| Biodelivery Sciences International, Inc. | 2 | $33 |
| Globus Medical | 1 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Averitas Pharma Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $23 |
| Amgen | 1 | $23 |
| Spinal Simplicity, LLC | 1 | $21 |
| SPR Therapeutics, Inc | 1 | $19 |
| Convatec Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADAPTIVESTIM$2,891
- TenJet$1,500
- SpineJet$1,500
- AlloJet$1,500
- INTELLIS ADAPTIVESTIM$1,412
- PROCLAIM$796
- SYNCHROMEDII$459
- INTELLIS$441
- Intracept$307
- GENERAL PAIN MANAGEMENT$238
- EXPAREL$221
- INCEPTIV$171
- Stimrouter for pain$167
- WaveWriter Alpha Prime 16$147
- SPECTRA WAVEWRITER$144
- GENERAL - THERAPIES$141
- PAINTEQ$138
- SYNCHROMED$125
- OCTRODE$121
- Vanta$118
How this compares
$20,766 in reported general payments places this provider in the 90th percentile of 22 interventional pain medicine providers in Massachusetts.
See all interventional pain medicine providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 93 | $1,570 |
| Oxycodone Hcl | 69 | $1,006 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $694 |
| Tramadol Hcl | 53 | $659 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $651 |
| Cyclobenzaprine Hcl | 40 | $461 |
| Gabapentin | 53 | $448 |
| Duloxetine Hcl | 13 | $212 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 14 | $116 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Boston
- Warren Mackie-JenkinsBoston$65K
- Mark JonesBoston$48K
- Elvis GuzmanBoston$4K
- David DibenedettoWaltham$17K
- Anil KumarStoneham$8K
- Omar QureshiFitchburg$7K
- Rami RustumMethuen$6K
- Janet PearlFramingham$5K
- Yuri KhibkinHolyoke$5K
- Erica BialBurlington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.